U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C13H13N3O3
Molecular Weight 259.2606
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYCLOBENDAZOLE

SMILES

COC(=O)NC1=NC2=CC(=CC=C2N1)C(=O)C3CC3

InChI

InChIKey=OXLKOMYHDYVIDM-UHFFFAOYSA-N
InChI=1S/C13H13N3O3/c1-19-13(18)16-12-14-9-5-4-8(6-10(9)15-12)11(17)7-2-3-7/h4-7H,2-3H2,1H3,(H2,14,15,16,18)

HIDE SMILES / InChI

Description

Cyclobendazole, a benzimidazole derivative, is an anthelmintic drug. It is a microtubule synthesis inhibitor.

Originator

Janssen
53

Approval Year

Unknown
149,124

Targets

Primary TargetPharmacologyConditionPotency
microtubule polymerization
21
Inhibitor
8,504

Conditions

ConditionModalityTargetsHighest PhaseProduct
Helminthiasis
39
 Curative
Approved
8,583
Ciclobendazole

Doses

AEs

PubMed

Patents

US20040224012
1
WO1994028887A1
3
WO2002058697A1
1
WO2012088441A1
1

Sample Use Guides

In Vivo Use Guide
Oxyuriasis treatment: 50 children were treated twice with 100 mg of cyclobendazole each, at a weekly interval
Route of Administration: Oral
In Vitro Use Guide
Cyclobendazole inhibited G. lamblia growth with IC50 0.047 ug/ml.
ACTIVE MOIETY
Structure of CYCLOBENDAZOLE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966